Researchers made and tested several compounds similar to an HIV drug, called nelfinavir, which has been known to incidentally block a key enzyme other than the HIV protein. The enzyme it blocks is similar to an enzyme in Streptococcus pyogenes, the pathogen responsible for more than 600 million illnesses and 500,000 deaths worldwide every year.
By blocking S. pyogenes, the drug may also be able to stop the pathogen’s ability to produce a toxin called streptolysin S, or SLS.
With additional research, scientists may be able to understand exactly how the bacteria works and how drugs like nelfinavir may play a role in new therapies to kill the pathogen.
More articles on infection control:
Minnesota hospitals make more mistakes, but cause fewer deaths
FDA seeks clarity from scope manufacturers on cleaning methods
Childhood pneumonia costs US $1B annually
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.